Xofigo radium 223 for cancer treatment.
Active Awarded Last action
- Contract number
- 36C25626N0492
- Awardee
-
Bayer Healthcare Pharmaceuticals Inc. UEI V1EVGCK7XES8 Part of Bayer Aktiengesellschaft
- Awarding agency
-
Veterans Integrated Service Network 16
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $386,860
Award facts
- Contract value 100% obligated
- $386,860.00 Current and potential, with all options
- Completion date 53% complete
- Current and potential, with all options
- Funding agency
- Veterans Integrated Service Network 17 Veterans Health Administration, Department of Veterans Affairs
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
About this award
Bayer Healthcare Pharmaceuticals Inc. received a $386,860 firm fixed-price delivery order from the Department of Veterans Affairs' Veterans Integrated Service Network 17 on April 10, 2026, for Xofigo (radium-223 dichloride), a specialized radiopharmaceutical used to treat castration-resistant prostate cancer. The delivery order, which is not designated as a small business set-aside, will be performed in Dublin, Ohio, with an ultimate completion date of April 9, 2027. This award is issued under the company's $840 million multiple-award Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs maintained with the VA, which enables rapid procurement of critical pharmaceutical products across federal agencies at pre-negotiated pricing.
Bayer Healthcare Pharmaceuticals Inc., a subsidiary of Germany-based Bayer AG, is a major supplier of specialized pharmaceutical and radiopharmaceutical products to the federal healthcare system. The company also maintains a specialized $6.8 million Blanket Purchase Agreement with the VA National Acquisition Center, effective through October 5, 2026, specifically covering Xofigo and Adempas medications. Bayer's federal contracting activity reflects its established position as a reliable supplier of single-source and limited-manufacturer medications essential to veteran healthcare programs, with delivery orders consistently issued across multiple Veterans Integrated Service Networks and VA medical facilities throughout the country.
Quick answers
Who was awarded contract 36C25626N0492?
36C25626N0492 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 16 (Veterans Health Administration) on April 10, 2026.
How much is contract 36C25626N0492 worth?
The government has obligated $386,860 on 36C25626N0492.
Which agency awarded contract 36C25626N0492?
Veterans Integrated Service Network 16 (Veterans Health Administration) awarded 36C25626N0492, with funding from Veterans Integrated Service Network 17 (Veterans Health Administration).
Is contract 36C25626N0492 an order under another contract?
Yes. 36C25626N0492 is a delivery order under 36F79720D0237, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25626N0492 competed?
The extent of competition for 36C25626N0492 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award